Kadimastem Ltd reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was ILS 12.01 million compared to ILS 22.72 million a year ago. Basic loss per share from continuing operations was ILS 2.8. Diluted loss per share from continuing operations was ILS 2.8.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
488.9 ILa | +2.07% | -3.85% | -17.55% |
28/03 | Kadimastem Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
28/02 | IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company | MT |
1st Jan change | Capi. | |
---|---|---|
-17.55% | 5.5M | |
+3.91% | 109B | |
+10.87% | 105B | |
0.00% | 22.25B | |
-13.14% | 22.09B | |
-7.63% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- KDST Stock
- News Kadimastem Ltd
- Kadimastem Ltd Reports Earnings Results for the Full Year Ended December 31, 2023